SARMs für den Muskelaufbau

The Research Case for Selective Androgen Receptor Modulators

If your research focus is skeletal muscle hypertrophy, strength output, or bone density, the compounds in this category represent the most advanced tools currently available in the SARM class.

Each has been selected for its documented anabolic activity, its tissue selectivity, and the strength of the evidence base behind it.

SARMs in this category work by selectively binding to androgen receptors in muscle and bone tissue. Unlike traditional anabolic androgens, they are designed to deliver targeted anabolic activity while reducing interactions with non-target tissues, such as the prostate. This selectivity is what makes them the subject of sustained clinical investigation.

Compounds in This Category

RAD-140 (Testolone)

The most potent compound in this range. Preclinical data in rats and primates confirmed strong anabolic signalling in muscle with minimal androgenic activity in the prostate. [1] RAD-140 has since progressed to Phase 1 human evaluation. [2]

Best suited to: intermediate and advanced users, bulking cycles, strength-focused protocols.

LGD-4033 (Ligandrol)

Backed by a Phase 1 randomised, placebo-controlled trial in 76 healthy men. Subjects receiving 1mg daily of Ligandrol for 21 days showed a statistically significant increase in lean body mass of 1.21kg, with no serious adverse events reported. [3]

Best suited to: lean mass research, dose-response studies, first-time SARM cycles.

YK-11

Operates through a dual mechanism: AR agonism and potential myostatin inhibition via follistatin expression. [4] Makes it a compound of particular interest for researchers studying upper-limit muscle development responses.

YK-11 is best suited for advanced research protocols and combination stacks.

Quality Assurance

All compounds are:

• Third-party tested to 99%+ purity.
• Supplied with batch-specific certificates of analysis.
• Sold strictly for research and laboratory purposes.

Not approved for human use. WADA prohibits all compounds in this category under the anabolic agents classification.

Sources:

[1] Miller, C. P., Shomali, M., Lyttle, C. R., et al. (2011). Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140. ACS Medicinal Chemistry Letters, 2(2), 124-129. https://doi.org/10.1021/ml1002508

[2] LoRusso, P., Hamilton, E., Ma, C., et al. (2022). A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer. Clinical Breast Cancer, 22(1), 67-77. https://doi.org/10.1016/j.clbc.2021.08.003

[3] Basaria, S., Collins, L., Dillon, E. L., et al. (2013). The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. The Journals of Gerontology: Series A, 68(1), 87-95. https://doi.org/10.1093/gerona/gls078

[4] Kanno, Y., Hikosaka, R., Zhang, S. Y., et al. (2013). Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts via follistatin expression. Biological and Pharmaceutical Bulletin, 36(9), 1460-1465. https://doi.org/10.1248/bpb.b13-00430